Uroplasty Appoints Suranjan Roychowdhury, Ph.D. to New Vice President of Research & Development and Clinical Affairs Role
Experienced Executive in Development and Commercialization of Medical Devices to Assume Key New Position
MINNEAPOLIS, Jan. 27, 2014 /PRNewswire/ — Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it has appointed Dr. Suranjan Roychowdhury as Vice President of Research & Development and Clinical Affairs. This newly created position within the Uroplasty organization was established to provide focus, oversight and guidance to the Company’s product pipeline and clinical trials. Dr. Roychowdhury joins Uroplasty with more than 20 years of functional leadership experience and success in the development and commercialization of implantable and disposable medical devices.
“This new position adds an important element to our strategic direction and product development capabilities. Suranjan’s highly relevant background and depth of experience will enable him to immediately add value and provide direction to our R&D initiatives, as well as lead our clinical programs,” said Rob Kill, President & CEO.
Dr. Roychowdhury served for more than eight years in advancing executive roles with American Medical Systems, including leadership of R&D as well as the Clinical, Regulatory, and Healthcare Economics functions for the $230 million Men’s Health division. Most recently, Dr. Roychowdhury was with Vascular Solutions, a Minnesota-based cardiovascular medical device company. He has also served in executive roles with Sulzer Spine-Tech (now Zimmer Spine), Boston Scientific, and Schneider USA (Pfizer).
Dr. Roychowdhury holds a B.Tech in Metallurgical Engineering from the Indian Institute of Technology at Varanasi, and M.S. and Ph.D. degrees in Materials Science & Engineering from the University of Delaware. He is the author of several publications on urology and cardiovascular topics. In addition, he holds 20 issued US patents for medical devices in Cardiology, Orthopedics, Urology and Drug Delivery.
About Overactive Bladder
Overactive bladder (OAB) is a chronic condition that affects approximately 41 million US adults. The symptoms include urinary urgency, frequency and urge incontinence. The Urgent PC Neuromodulation System is the only FDA cleared device that delivers Percutaneous Tibial Nerve Stimulation (PTNS) therapy.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only commercially available FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
Brett Reynolds, SVP and CFO
Leigh Salvo (Investors)/Janine McCargo (Business Media)
SOURCE Uroplasty, Inc.